Durable Disease Control With Atezolizumab Plus Bevacizumab but Limited Post‐Progression Outcomes: A Multicenter Real‐World Study in Advanced Hepatocellular Carcinoma
Open Access
- 18 February 2026
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 15 (2) , e71655
Abstract
Introduction: Atezolizumab plus bevacizumab (Atez/Bev) has become the standard first‐line therapy for advanced hepatocellular carcinoma (HCC), but optimal second‐line strategies remain unclear. This multicenter retrospective study compared survival outcomes and tumor control among first‐line regimens and evaluated post‐progression efficacy. Methods: We retrospectively analyzed 1542 patients with advanced HCC who received sorafenib (SOR), lenvatinib (LEN), or Atez/Bev between 2009 and 2022. The main cohort ( n = 612) excluded patients who underwent concomitant or inter‐line locoregional therapy or entered clinical trials after first‐line treatment. Overall survival (OS), progression‐free survival (PFS), post‐progression survival (PPS), duration of disease control (DDC), and duration of response (DOR) were estimated by Kaplan–Meier analysis and compared by the log‐rank test. The impact of disease control and objective response on OS was assessed using time‐dependent Cox models. Results: Median OS was 15.4 months for SOR, 13.1 for LEN, and 20.6 for Atez/Bev ( p = 0.002); Median PFS was 3.5, 5.7, and 7.5 months, respectively ( p < 0.001); and median PPS was 10.8, 6.4, and 9.0 months, respectively ( p = 0.049). Atez/Bev achieved the longest DDC (8.5 months) and DOR (22.1 months). Disease control and objective response were associated with improved OS (HR: 0.51/0.42 for SOR, 0.54/0.62 for LEN, 0.34/0.35 for Atez/Bev). After progression, median second‐line PFS was 5.5 months for SOR, 2.5 for LEN, and 3.0 for Atez/Bev ( p = 0.001). Conclusion: Atez/Bev provided superior survival and durable tumor control; however, post‐progression outcomes remained unsatisfactory, underscoring the need for improved second‐line approaches after Atez/Bev failure.Keywords
This publication has 35 references indexed in Scilit:
- Deterioration of liver function and aging disturb sequential systemic therapy for unresectable hepatocellular carcinomaScientific Reports, 2022
- Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real studyEuropean Journal of Cancer, 2022
- Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%Journal of Clinical Oncology, 2021
- Comparison of Duration of Response vs Conventional Response Rates and Progression-Free Survival as Efficacy End Points in Simulated Immuno-oncology Clinical TrialsJAMA Network Open, 2021
- Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective StudyLiver Cancer, 2021
- Systemic Therapy and Sequencing Options in Advanced Hepatocellular CarcinomaJAMA Oncology, 2020
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular CarcinomaNew England Journal of Medicine, 2020
- When Can Intermediate Outcomes Be Used as Surrogate Outcomes?JAMA, 2020
- Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenibInvestigational New Drugs, 2016
- Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumorsCancer Cell, 2005